Stockreport

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma, Inc.  (TRAW) 
PDF Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,  Ratutrel [Read more]